Clinical trials of therapies directed against a gene called mTOR in glioblastoma cancer have had disappointing results. Drug resistance of glioblastoma cancer cells to mTOR-targeted drugs has limited their usefulness. Our data show how the glioblastoma cancer cells become resistant to mTOR-targetd drugs in human glioblastoma cancer cell cultures and points us toward new therapeutic strategies.